Advertisement
BCRX or CAPR or DERM
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BCRX’s FA Score shows that 0 FA rating(s) are green whileCAPR’s FA Score has 0 green FA rating(s), and DERM’s FA Score reflects 0 green FA rating(s).
- BCRX’s FA Score: 0 green, 5 red.
- CAPR’s FA Score: 0 green, 5 red.
- DERM’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BCRX’s TA Score shows that 4 TA indicator(s) are bullish while CAPR’s TA Score has 5 bullish TA indicator(s), and DERM’s TA Score reflects 3 bullish TA indicator(s).
- BCRX’s TA Score: 4 bullish, 5 bearish.
- CAPR’s TA Score: 5 bullish, 5 bearish.
- DERM’s TA Score: 3 bullish, 6 bearish.
Price Growth
BCRX (@Biotechnology) experienced а -0.80% price change this week, while CAPR (@Biotechnology) price change was -29.45% , and DERM (@Pharmaceuticals: Other) price fluctuated +0.87% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.69%. For the same industry, the average monthly price growth was +18.51%, and the average quarterly price growth was +31.06%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +62.47%. For the same industry, the average monthly price growth was +4.88%, and the average quarterly price growth was +67.74%.
Reported Earning Dates
BCRX is expected to report earnings on Oct 29, 2025.
CAPR is expected to report earnings on Nov 12, 2025.
DERM is expected to report earnings on Nov 05, 2025.
Industries' Descriptions
@Biotechnology (+2.69% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Other (+62.47% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| BCRX | CAPR | DERM | |
| Capitalization | 1.83B | 328M | 73.4M |
| EBITDA | 47.6M | -55.78M | -5.69M |
| Gain YTD | 15.957 | -48.007 | 78.517 |
| P/E Ratio | N/A | N/A | N/A |
| Revenue | 503M | 17.4M | 79.9M |
| Total Cash | 295M | 145M | 24.7M |
| Total Debt | 795M | 1.25M | 131K |
BCRX | CAPR | DERM | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 53 | 53 | 31 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 50 Fair valued | 74 Overvalued | 67 Overvalued | |
PROFIT vs RISK RATING 1..100 | 74 | 84 | 100 | |
SMR RATING 1..100 | 100 | 98 | 97 | |
PRICE GROWTH RATING 1..100 | 51 | 65 | 40 | |
P/E GROWTH RATING 1..100 | 100 | 100 | 45 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 38 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BCRX's Valuation (50) in the Biotechnology industry is in the same range as DERM (67) and is in the same range as CAPR (74). This means that BCRX's stock grew similarly to DERM’s and similarly to CAPR’s over the last 12 months.
BCRX's Profit vs Risk Rating (74) in the Biotechnology industry is in the same range as CAPR (84) and is in the same range as DERM (100). This means that BCRX's stock grew similarly to CAPR’s and similarly to DERM’s over the last 12 months.
DERM's SMR Rating (97) in the Biotechnology industry is in the same range as CAPR (98) and is in the same range as BCRX (100). This means that DERM's stock grew similarly to CAPR’s and similarly to BCRX’s over the last 12 months.
DERM's Price Growth Rating (40) in the Biotechnology industry is in the same range as BCRX (51) and is in the same range as CAPR (65). This means that DERM's stock grew similarly to BCRX’s and similarly to CAPR’s over the last 12 months.
DERM's P/E Growth Rating (45) in the Biotechnology industry is somewhat better than the same rating for BCRX (100) and is somewhat better than the same rating for CAPR (100). This means that DERM's stock grew somewhat faster than BCRX’s and somewhat faster than CAPR’s over the last 12 months.
| BCRX | CAPR | DERM | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 2 days ago 90% | N/A |
| Stochastic ODDS (%) | 1 day ago 83% | 2 days ago 88% | 2 days ago 82% |
| Momentum ODDS (%) | 1 day ago 86% | 2 days ago 85% | 2 days ago 81% |
| MACD ODDS (%) | N/A | 2 days ago 90% | 2 days ago 86% |
| TrendWeek ODDS (%) | 1 day ago 80% | 2 days ago 85% | 2 days ago 89% |
| TrendMonth ODDS (%) | 1 day ago 82% | 2 days ago 83% | 2 days ago 87% |
| Advances ODDS (%) | 7 days ago 79% | 7 days ago 85% | 6 days ago 87% |
| Declines ODDS (%) | 5 days ago 79% | 2 days ago 85% | 29 days ago 87% |
| BollingerBands ODDS (%) | 1 day ago 77% | 2 days ago 87% | 2 days ago 90% |
| Aroon ODDS (%) | 1 day ago 84% | 2 days ago 83% | 2 days ago 85% |
Advertisement
CAPR and
Correlation & Price change
A.I.dvisor tells us that CAPR and SNDX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CAPR and SNDX's prices will move in lockstep.
| Ticker / NAME | Correlation To CAPR | 1D Price Change % | ||
|---|---|---|---|---|
| CAPR | 100% | -2.84% | ||
| SNDX - CAPR | 31% Poorly correlated | -6.50% | ||
| MDGL - CAPR | 30% Poorly correlated | -2.73% | ||
| WVE - CAPR | 30% Poorly correlated | -1.66% | ||
| CORT - CAPR | 30% Poorly correlated | -1.87% | ||
| ABEO - CAPR | 30% Poorly correlated | +0.51% | ||
More | ||||
DERM and
Correlation & Price change
A.I.dvisor tells us that DERM and AQST have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DERM and AQST's prices will move in lockstep.
| Ticker / NAME | Correlation To DERM | 1D Price Change % | ||
|---|---|---|---|---|
| DERM | 100% | -5.80% | ||
| AQST - DERM | 32% Poorly correlated | -0.25% | ||
| CHRS - DERM | 27% Poorly correlated | -10.56% | ||
| ETON - DERM | 24% Poorly correlated | -0.76% | ||
| CRDL - DERM | 23% Poorly correlated | -3.01% | ||
| DRMA - DERM | 22% Poorly correlated | +0.18% | ||
More | ||||